play book. announce we are going to do something , announce we have lodged ip for it. (but also they are only funded for 1-2 assets) not the 28 assets. the ip laps as you must show proof with data. (that is clinical trial validation that your ip claim is true). it gets retail excited from soo many exciting announcements much in the same way that retail loved the last 'exchange dynamics' and had a nice run - rinse and repeat due to the sp.
the ethical issues with canvalante (and I'm no insider maybe there are others that haven't been voiced) is around drug product owner and that they were drs providing patent advice. it's interesting how so many ended up needing to use their product and not another. it's like going to the slacker family (oxy) and asking what is the best thing for your issue. conflict of interests.
that might have no kick back on Ihl but it doesn't bode well when industry are talking about how shocking it is. it would go back to that 'body of evidence'.
it also questions when posters say the team are top tier how much do they really know / have the skills to judge.
